Coherus Biosciences: Funding, Investors & Team (Sep 2026)
Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates.
Coherus Biosciences has raised $200M across 3 funding rounds on record, the most recent an undisclosed round of $50.1M announced in Feb 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Coherus Biosciences Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Coherus Biosciences Funding Rounds
Coherus Biosciences raised $100M in a Post-IPO Debt announced in Jan 2022.
1.3 years later, an undisclosed round of $50.0M was announced in May 2023.
2.8 years later, an undisclosed round of $50.1M was announced in Feb 2026.
Coherus Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Coherus Biosciences Funding Compared to Other Biotechnology Startups
Coherus Biosciences' latest round of $50.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Coherus Biosciences in Biotechnology and Redwood City
Companies Similar to Coherus Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Coherus Biosciences Funding FAQs
What does Coherus Biosciences do?
Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates.
How much funding has Coherus Biosciences raised?
Coherus Biosciences has raised $200M across 3 rounds on record. The most recent is an undisclosed round of $50.1M announced in Feb 2026.
When did Coherus Biosciences last raise funding?
Coherus Biosciences' most recent funding round on record is an undisclosed round of $50.1M, announced in Feb 2026.
Who is the CEO of Coherus Biosciences?
Dennis Lanfear is listed as CEO at Coherus Biosciences.
Where is Coherus Biosciences headquartered?
Coherus Biosciences is based in Redwood City, California, United States.
How many employees does Coherus Biosciences have?
Coherus Biosciences is in the 251-500 employee band.
How does Coherus Biosciences' funding compare to other Biotechnology startups?
Coherus Biosciences' latest round of $50.1M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Coherus Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Coherus Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.